Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
NCT07158489
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
47
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
DRUG:
Gemcitabine + Ivonescimab
Sponsor
Swiss Cancer Institute